Comparable stake leader
Soleus Capital Master Fund, L.P.
SEC ownership of ESSA Pharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001633932.
Disclosed value leader
BML Investment Partners, L.P.
Comparable rows
4/10
Latest evidence
30 Sep 2025
- SEC evidence covered
- 13D/G and 3/4/5
- Largest SEC-reported holder
- Soleus Capital Master Fund, L.P.
- Latest 13D/G holder
- Soleus Capital Master Fund, L.P.
- Latest parsed evidence date
- 30 Sep 2025
- CIK
- 0001633932
- Location
- Vancouver
Ownership snapshot
2 signals
Issuer
2 identity fields
Ownership snapshot
Top shareholders of ESSA Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Capital Master Fun...
Disclosed value leader
BML Investment Partners, ...
Comparable rows
4/10
Latest evidence
30 Sep 2025
13D/G
3/4/5
Lead comparable stake: 9.8%
6 rows are not safely comparable across share classes.
13D/G row: Soleus Capital Master Fund, L.P.
Showing 1-8 of 10 holder rows.
Quick read
Soleus Capital Master Fund, L.P. leads the comparable SEC ownership view at 9.8%.
4 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 4
Soleus Capital Master Fund, L.P.
9.8%
BML Investment Partners, L.P.
9.5%
MORGAN STANLEY
4%
RTW INVESTMENTS, LP
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. |
13D/G
|
9.8%
|
$7,415,444
4,362,026 shares
|
+$3,570,000 | 17 Jul 2025 |
| BML Investment Partners, L.P. |
13D/G
|
9.5%
|
$7,598,783
4,221,546 shares
|
+$68,981 | 24 Apr 2025 |
| MORGAN STANLEY |
13D/G
|
4%
|
$456,975
1,904,062 shares
|
$0 | 30 Sep 2025 |
| RTW INVESTMENTS, LP |
13D/G
|
2.5%
|
$2,003,404
1,113,002 shares
|
$0 | 31 Dec 2024 |
| Peter Virsik |
3/4/5
Chief Operating Officer
|
—
mixed-class rows
|
$46,889
117,776 shares
mixed-class rows
|
— | 07 Oct 2024 |
| Alessandra Cesano |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
200,000 shares
|
— | 25 Mar 2024 |
| Gary Sollis |
3/4/5
Director
|
—
class O/S missing
|
—
50,000 shares
|
— | 25 Mar 2024 |
| Philip W. Kantoff |
3/4/5
Director
|
—
class O/S missing
|
—
50,000 shares
|
— | 25 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$293.
Buys
$0
Insiders: 0
Sells
$293
Insiders: 1
Net
-$293
Shares: -156
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 156
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 156 | $0 | $293 | -$293 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to ESSA Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Peter Virsik
Net 12M change
-$293
Latest report
09 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Peter Virsik | Chief Operating Officer | $46,889 | Filing P/S | 07 Oct 2024 | ||
| BVF PARTNERS L P/IL | 10%+ Owner | $0 | -$293 | -100% | Mixed | 09 Oct 2025 |
| BIOTECH GROWTH N V | 10%+ Owner | $0 | Mixed | 01 Nov 2024 | ||
| Franklin M. Berger | Director | $0 | Mixed | 09 Oct 2025 | ||
| Richard M. Glickman | Director | $0 | Mixed | 09 Oct 2025 | ||
| John Alexander Martin | Director | $0 | Mixed | 09 Oct 2025 | ||
| Marella Thorell | Director | $0 | Mixed | 09 Oct 2025 | ||
| David Ross Parkinson | President and CEO, Director | $0 | Mixed | 09 Oct 2025 | ||
| David S. Wood | Chief Financial Officer | $0 | Mixed | 09 Oct 2025 | ||
| Scott Requadt | Director | $0 | Mixed | 09 Oct 2025 | ||
| Philip W. Kantoff | Director | Mixed | 25 Mar 2024 | |||
| Lauren Merendino | Director | Mixed | 25 Mar 2024 | |||
| Gary Sollis | Director | Mixed | 25 Mar 2024 | |||
| Alessandra Cesano | Chief Medical Officer | Mixed | 25 Mar 2024 | |||
| Sanford S. Zweifach | Director | Mixed | 25 Mar 2024 |
Recent insider transactions for ESSA Pharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Ross Parkinson | EPIX | Common Shares | Disposed to Issuer | -100% | -65,675 | 0 | 09 Oct 2025 | Direct | ||
| David S. Wood | EPIX | Common Shares | Disposed to Issuer | -100% | -33,343 | 0 | 09 Oct 2025 | Direct | ||
| Franklin M. Berger | EPIX | Common Shares | Disposed to Issuer | -100% | -784,404 | 0 | 09 Oct 2025 | Direct | ||
| Richard M. Glickman | EPIX | Common Shares | Disposed to Issuer | -100% | -43,240 | 0 | 09 Oct 2025 | Direct | ||
| Scott Requadt | EPIX | Common Shares | Disposed to Issuer | -100% | -30,002 | 0 | 09 Oct 2025 | Direct | ||
| John Alexander Martin | EPIX | Common Shares | Disposed to Issuer | -100% | -14,299 | 0 | 09 Oct 2025 | Direct | ||
| Marella Thorell | EPIX | Common Shares | Disposed to Issuer | -100% | -2,881 | 0 | 09 Oct 2025 | Direct | ||
| Bvf Partners L P/Il | EPIX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -11,481,685 | 0 | 09 Oct 2025 | Direct | ||
| Bvf Partners L P/Il | EPIX | Common Stock | Sale | -0.03% | $293 | $1.88 | -156 | 560,797 | 05 Aug 2025 | Direct |
| Bvf Partners L P/Il | EPIX | Common Stock | Exercise of in-the-money or at-the-money derivative security | 89.2% | 2,920,000 | 6,194,224 | 05 Aug 2025 | Direct | ||
| Bvf Partners L P/Il | EPIX | Pre-funded Warrants | Exercise of in-the-money or at-the-money derivative security | -100% | -2,920,000 | 0 | 05 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.